Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions

To analyze the urinary biomarkers in men with lower urinary-tract symptoms (LUTS) and identify interstitial cystitis/bladder pain syndrome (IC/BPS) from other dysfunctions (LUTDs) by levels of characteristic biomarkers. In total, 198 LUTS were prospectively enrolled urine samples collected before intervention or medical treatment. Videourodynamic studies routinely performed LUTDs diagnosed as having bladder-outlet obstruction (BOO) such bladder-neck dysfunction, benign prostatic obstruction, poor relaxation external sphincter (PRES); bladder dysfunction detrusor overactivity (DO), hypersensitive (HSB), IC/BPS. Patients suspicious IC/BPS further confirmed cystoscopic hydrodistention under anesthesia. The investigated for 11 inflammatory including eotaxin, IL-6, IL-8, CXCL10, MCP-1, MIP-1β, RANTES, TNF-α, NGF, BDNF, PGE2; 3 oxidative stress 8-OHdG, 8-isoprostane, TAC. biomarker analyzed between LUTD subgroups patients. results this study revealed that among patients, was 48, BOO 66, DO 25, HSB 27, PRES 15, normal 17. had a higher pressure index than IC/BPS, whereas patients BOO, smaller cystometric capacity subgroups. Among biomarkers, significantly TAC all By combination different either alone combination, highest sensitivity, specificity, positive predictive value, negative value to discriminate subgroups, DO, Inflammatory MCP-1 8-OHdG TAC, although did not have diagnostic male concluded using TNF-α eotaxin levels, can be used LUTS.